|
Pfizer
|
ZYVOX
| Approved in USA | Anti-infectives for systemic use |
|
Pfizer
|
Zyrtec
| Approved in USA | Respiratory system |
|
Pfizer
|
Zyrtec
| Approved in USA | Dermatologicals |
|
Lilly
|
Zyprexa
| Approved in USA | Nervous system |
|
Bausch & Lomb
|
Zylet
| Approved in USA | Sensory organs |
|
Critical Therapeutics
|
Zyflo
| accomplished Phase II | Dermatologicals |
|
Critical Therapeutics
|
Zyflo
| Approved in USA | Respiratory system |
|
OXiGENE
|
Zybrestat
| in Phase I | Antineoplastic & immunomodulating agents
|
|
OXiGENE
|
Zybrestat
| accomplished Phase II | Antineoplastic & immunomodulating agents
|
|
OXiGENE
|
Zybrestat
| in Phase II | Antineoplastic & immunomodulating agents
|
|
OXiGENE
|
Zybrestat
| accomplished Phase II | Sensory organs |
|
Biovail
|
Zovirax
| Approved in USA | Anti-infectives for systemic use |
|
AstraZeneca
|
ZOMIG
| Approved in USA | Nervous system |
|
Novartis
|
Zometa
| in Phase III | Antineoplastic & immunomodulating agents
|
|
Novartis
|
Zometa
| in Phase II | Musculoskeletal system |
|
Novartis
|
Zometa
| Approved in USA and EU, submitted for approval in Japan | Antineoplastic & immunomodulating agents
|
|
Ferring
|
ZOMACTON
| accomplished Phase III | Systemic hormonal preparations |
|
Biovail
|
Zolpidem ODT
| Approved in USA | Nervous system |
|
Pfizer
|
Zithromax
| Approved in USA | Anti-infectives for systemic use |
|
Barrier Therapeutics
|
Zimycan
| discontinued | Dermatologicals |